← All companies
AbCellera Biologics Inc.
ABCL - CIK 0001703057
Market cap$1.57 B
Rank#2295
SEC filings297
AbCellera Biologics Inc. trades as ABCL and has a market capitalization of $1.57 B, making it the #2295 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $75.13M, up 160.6% from the prior year and net income of -$146.41M. This page tracks AbCellera Biologics Inc. through 297 SEC filings, with financial statements and metrics updated as new reports are filed.
Key metrics
Revenue (latest FY)$75.13MFY 2025
Net income (latest FY)-$146.41MFY 2025
Operating cash flow (latest FY)-$131.29MFY 2025
Total assets (latest FY)$1.36BFY 2025
Net margin-194.9%latest FY
Financial performance
Over the last 6 fiscal years AbCellera Biologics Inc.'s revenue grew from $11.61M to $75.13M, a compound annual growth rate of 36.5%. Net profit margin compressed from -19.0% to -194.9% over the same period - every figure below comes from the company's audited annual filings.
Key statistics
- Market cap
- $1.57 B
- Share price (derived)market cap / shares outstanding
- $5.13
- EPS (diluted)FY 2025
- $-0.49
- Shares outstandingas of 2026-05-07
- 0.31B
- Total equityas of 2026-03-31
- $938.08M
- Return on equity
- -15.6%
- Cash & equivalentsas of 2026-03-31
- $77.06M
- Current ratioas of 2026-03-31
- 14.05
Latest filings
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-18 |
| Quarterly report | 10-Q | 2026-05-11 |
| Major company event | 8-K | 2026-05-11 |
| SCHEDULE 13G/A | - | 2026-05-07 |
| Annual report to shareholders | ARS | 2026-04-29 |
| Proxy materials | DEFA14A | 2026-04-29 |
| Proxy statement | DEF 14A | 2026-04-29 |
| Insider trade | 4 | 2026-03-02 |
Recent press releases
- AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL6352026-05-11
- AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call2026-04-20
- AbCellera to Report First Quarter 2026 Financial Results on May 11, 20262026-04-01
- AbCellera Reports Full Year 2025 Business Results2026-02-24
- AbCellera to Report Full Year 2025 Financial Results on February 24, 20262026-01-22
Similar companies
The largest companies sharing AbCellera Biologics Inc.'s SEC industry classification (pharmaceutical preparations).
Frequently asked questions
What is AbCellera Biologics Inc.'s market cap?
AbCellera Biologics Inc. (ABCL) has a market capitalization of $1.57 B as of 2026-06-10, ranking #2295 among US-listed companies.
How much revenue does AbCellera Biologics Inc. make?
AbCellera Biologics Inc. reported revenue of $75.13M for fiscal year 2025, an increase of 160.6% year over year.
Is AbCellera Biologics Inc. profitable?
In its latest fiscal year AbCellera Biologics Inc. reported a net loss of $146.41M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.